Patch testing a patient with allergic contact hand dermatitis who is taking infliximab.
We report the case of a patient who developed allergic contact hand dermatitis while receiving infliximab infusions for psoriasis and psoriatic arthritis. Patch testing showed multiple positive allergens. To our knowledge, this is the first case report of successful patch testing in a patient receiving tumor necrosis factor-alpha (TNF-alpha) blockade therapy. TNF-alpha blockers do not necessarily suppress allergic contact hypersensitivity and are not an absolute contraindication to patch testing.
Rosmarin
David
D
Department of Dermatology, Tufts-New England Medical Center, Boston, Massachusetts, USA. dmr275@med.nyu.edu
Bush
Michelle
M
Scheinman
Pamela L
PL
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D017449:Dermatitis, Allergic Contact / Q000175:diagnosis* / Q000209:etiology* / Q000517:prevention & control; D017575:Gloves, Protective; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D006801:Humans; D000069285:Infliximab; D008297:Male; D008669:Metallurgy; D008670:Metals; D008875:Middle Aged; D009784:Occupational Diseases / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D016273:Occupational Exposure / Q000032:analysis; D009821:Oils; D011565:Psoriasis / Q000188:drug therapy; D012882:Skin Tests; D012997:Solvents; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D008670:Metals; D009821:Oils; D012997:Solvents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab